Treatment of relapsed/refractory MCL

2.

Alaggio

R

,

Amador

C

,

Anagnostopoulos

I

, et al.

The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1720

-

1748

.

3.

Campo

E

,

Jaffe

ES

,

Cook

JR

, et al.

The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee

.

Blood

.

2022

;

140

(

11

):

1229

-

1253

.

4.

Macintyre

E

,

Döhner

K

,

Grønbæk

K

, et al.

Precision hematology: navigating the evolution of diagnostic classifications in the era of globalized medicine

.

Hemasphere

.

2024

;

8

(

4

):

e65

.

5.

Dreyling

M

,

Goy

A

,

Hess

G

, et al.

Long-term outcomes with ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up

.

Hemasphere

.

2022

;

6

(

5

):

e712

.

6.

Cheah

CY

,

Chihara

D

,

Romaguera

JE

, et al.

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

.

Ann Oncol

.

2015

;

26

(

6

):

1175

-

1179

.

7.

Scheubeck

G

,

Jiang

L

,

Hermine

O

, et al.

Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)

.

Leukemia

.

2023

;

37

(

9

):

1887

-

1894

.

8.

Aukema

SM

,

Hoster

E

,

Rosenwald

A

, et al.

Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network

.

Blood

.

2018

;

131

(

4

):

417

-

420

.

9.

Sarkozy

C

,

Chartier

L

,

Ribrag

V

, et al.

Validation of POD24 as a robust early clinical end point of poor survival in mantle cell lymphoma from 1280 patients on clinical trials [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

299

.

10.

Jares

P

,

Colomer

D

,

Campo

E

.

Molecular pathogenesis of mantle cell lymphoma

.

J Clin Invest

.

2012

;

122

(

10

):

3416

-

3423

.

11.

Nadeu

F

,

Martin-Garcia

D

,

Clot

G

, et al.

Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes

.

Blood

.

2020

;

136

(

12

):

1419

-

1432

.

12.

Jain

P

,

Zhang

S

,

Kanagal-Shamanna

R

, et al.

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

.

Blood Adv

.

2020

;

4

(

6

):

1038

-

1050

.

13.

Eskelund

CW

,

Dahl

C

,

Hansen

JW

, et al.

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

.

Blood

.

2017

;

130

(

17

):

1903

-

1910

.

14.

Ferrero

S

,

Rossi

D

,

Rinaldi

A

, et al.

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

.

Haematologica

.

2020

;

105

(

6

):

1604

-

1612

.

15.

Delfau-Larue

MH

,

Klapper

W

,

Berger

F

, et al.

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

.

Blood

.

2015

;

126

(

5

):

604

-

611

.

16.

Karolová

J

,

Kazantsev

D

,

Svatoň

M

, et al.

Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy

.

Am J Hematol

.

2023

;

98

(

10

):

1627

-

1636

.

17.

Yi

S

,

Yan

Y

,

Jin

M

, et al.

Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma

.

J Clin Invest

.

2022

;

132

(

3

):

e153283

.

18.

Dreyling

M

,

Buske

C

,

Cairoli

A

, et al.

Mantelzell-lymphom onkopedia

. Accessed 6 January 2024. https://www.onkopedia.com/de/onkopedia/guidelines/mantelzell-lymphom/@@guideline/html/index.html.

19.

Dreyling

M

,

Doorduijn

J

,

Giné

E

, et al.

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

.

Lancet

.

2024

;

403

(

10441

):

2293

-

2306

.

20.

Wang

ML

,

Rule

S

,

Martin

P

, et al.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

.

N Engl J Med

.

2013

;

369

(

6

):

507

-

516

.

21.

Dreyling

M

,

Jurczak

W

,

Jerkeman

M

, et al.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

.

Lancet

.

2016

;

387

(

10020

):

770

-

778

.

22.

Visco

C

,

Di Rocco

A

,

Evangelista

A

, et al.

Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

.

Leukemia

.

2021

;

35

(

3

):

787

-

795

.

23.

Visco

C

,

Malinverni

C

,

Florea

E

, et al.

Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

.

Hematol Oncol

.

2023

;

41

(

S2

):

474

-

475

.

24.

Villa

D

,

Jiang

A

,

Visco

C

, et al.

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma

.

Blood advances

.

2023

;

7

(

16

):

4576

-

4585

.

25.

Martin

P

,

Maddocks

K

,

Leonard

JP

, et al.

Postibrutinib outcomes in patients with mantle cell lymphoma

.

Blood

.

2016

;

127

(

12

):

1559

-

1563

.

26.

Wu

C

,

de Miranda

NF

,

Chen

L

, et al.

Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations

.

Oncotarget

.

2016

;

7

(

25

):

38180

-

38190

.

27.

Decombis

S

,

Bellanger

C

,

Le Bris

Y

, et al.

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

.

Blood

.

2023

;

142

(

18

):

1543

-

1555

.

28.

Mohanty

A

,

Sandoval

N

,

Das

M

, et al.

CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma

.

Oncotarget

.

2016

;

7

(

45

):

73558

-

73572

.

29.

Zhang

S

,

Jiang

VC

,

Han

G

, et al.

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

.

Nat Commun

.

2021

;

12

(

1

):

2877

.

30.

Rahal

R

,

Frick

M

,

Romero

R

, et al.

Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma

.

Nat Med

.

2014

;

20

(

1

):

87

-

92

.

31.

Vidal-Crespo

A

,

Rodriguez

V

,

Matas-Cespedes

A

, et al.

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

.

Haematologica

.

2017

;

102

(

11

):

e447

-

e451

.

32.

Lenz

G

,

Balasubramanian

S

,

Goldberg

J

, et al.

Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial

.

J Clin Oncol

.

2016

;

34

(

suppl 15

):

7570

.

33.

Chiron

D

,

Di Liberto

M

,

Martin

P

, et al.

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma

.

Cancer Discov

.

2014

;

4

(

9

):

1022

-

1035

.

34.

Rule

S

,

Dreyling

M

,

Goy

A

, et al.

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

.

Haematologica

.

2019

;

104

(

5

):

e211

-

e214

.

35.

Wang

M

,

Rule

S

,

Zinzani

PL

, et al.

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

.

Lancet (London, England)

.

2018

;

391

(

10121

):

659

-

667

.

36.

Le Gouill

S

,

Długosz-Danecka

M

,

Rule

S

, et al.

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

.

Haematologica

.

2024

;

109

(

1

):

343

-

350

.

37.

Song

Y

,

Zhou

K

,

Zou

D

, et al.

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

.

Blood

.

2022

;

139

(

21

):

3148

-

3158

.

38.

Byrd

JC

,

Hillmen

P

,

Ghia

P

, et al.

Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial

.

J Clin Oncol

.

2021

;

39

(

31

):

3441

-

3452

.

39.

Brown

JR

,

Eichhorst

B

,

Hillmen

P

, et al.

Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia

.

N Engl J Med

.

2023

;

388

(

4

):

319

-

332

.

40.

Tam

CS

,

Opat

S

,

D’Sa

S

, et al.

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

.

Blood

.

2020

;

136

(

18

):

2038

-

2050

.

41.

Jain

P

,

Romaguera

J

,

Srour

SA

, et al.

Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

.

Br J Haematol

.

2018

;

182

(

3

):

404

-

411

.

42.

Novak

U

,

Fehr

M

,

Schär

S

, et al.

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)

.

EClinicalMedicine

.

2023

;

64

:

102221

.

43.

Cohen

JB

,

Jegede

O

,

Portell

CA

, et al.

Ibrutinib and ixazomib in relapsed/refractory mantle cell lymphoma: Precog 0404 [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

6487

-

6488

.

44.

Jerkeman

M

,

Eskelund

CW

,

Hutchings

M

, et al.

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

.

Lancet Haematol

.

2018

;

5

(

3

):

e109-e116

.

45.

Maddocks

K

,

Christian

B

,

Jaglowski

S

, et al.

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

.

Blood

.

2015

;

125

(

2

):

242

-

248

.

46.

Wang

ML

,

Jurczak

W

,

Jerkeman

M

, et al.

Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma

.

N Engl J Med

.

2022

;

386

(

26

):

2482

-

2494

.

47.

Davids

MS

,

Roberts

AW

,

Kenkre

VP

, et al.

Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study

.

Clin Cancer Res

.

2021

;

27

(

17

):

4690

-

4695

.

48.

Handunnetti

SM

,

Anderson

MA

,

Burbury

K

, et al.

Three year update of the phase II ABT-199 (venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study [abstract]

.

Blood

.

2019

;

134

(

suppl 1

):

756

.

49.

Wang

M

,

Jurczak

W

,

Trněný

M

, et al.

Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 sympatico study [abstract]

.

Blood

.

2023

;

142

(

suppl 2

):

LBA-2

.

50.

Portell

CA

,

Wages

NA

,

Kahl

BS

, et al.

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma

.

Blood Adv

.

2022

;

6

(

5

):

1490

-

1498

.

51.

Le Gouill

S

,

Morschhauser

F

,

Chiron

D

, et al.

Long term follow-up of untreated/relapsing MCL patients with the ibrutinib, obinutuzumab, and venetoclax combination

.

Hematol Oncol

.

2023

;

41

(

S2

):

478

-

479

.

52.

Eyre

TA

,

Walter

HS

,

Iyengar

S

, et al.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

.

Haematologica

.

2019

;

104

(

2

):

e68

-

e71

.

53.

Zhao

S

,

Kanagal-Shamanna

R

,

Navsaria

L

, et al.

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients

.

Am J Hematol

.

2020

;

95

(

6

):

623

-

629

.

54.

Sawalha

Y

,

Goyal

S

,

Switchenko

JM

, et al.

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma

.

Blood Adv

.

2023

;

7

(

13

):

2983

-

2993

.

55.

Wang

M

,

Fayad

L

,

Wagner-Bartak

N

, et al.

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

.

Lancet Oncol

.

2012

;

13

(

7

):

716

-

723

.

56.

Goy

A

,

Sinha

R

,

Williams

ME

, et al.

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study

.

J Clin Oncol

.

2013

;

31

(

29

):

3688

-

3695

.

57.

Zinzani

PL

,

Vose

JM

,

Czuczman

MS

, et al.

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

.

Ann Oncol

.

2013

;

24

(

11

):

2892

-

2897

.

58.

Trněný

M

,

Lamy

T

,

Walewski

J

, et al.

Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial

.

Lancet Oncol

.

2016

;

17

(

3

):

319

-

331

.

59.

Wang

M

,

Schuster

SJ

,

Phillips

T

, et al.

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

.

J Hematol Oncol

.

2017

;

10

(

1

):

171

.

60.

McCulloch

R

,

Visco

C

,

Eyre

TA

, et al.

Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy

.

Br J Haematol

.

2020

;

189

(

4

):

684

-

688

.

61.

McCulloch

R

,

Lewis

D

,

Crosbie

N

, et al.

Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients

.

Br J Haematol

.

2021

;

193

(

2

):

290

-

298

.

62.

Gomez

EB

,

Ebata

K

,

Randeria

HS

, et al.

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor

.

Blood

.

2023

;

142

(

1

):

62

-

72

.

63.

Cohen

JB

,

Shah

NN

,

Jurczak

W

, et al.

Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

981

.

64.

Eyre

TA

,

Shah

NN

,

Dreyling

M

, et al.

BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma

.

Future Oncol

.

2022

;

18

(

36

):

3961

-

3969

.

65.

Wang

M

,

Munoz

J

,

Goy

A

, et al.

Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study

.

J Clin Oncol

.

2023

;

41

(

3

):

555

-

567

.

66.

Goy

A

,

Jacobson

CA

,

Flinn

IW

, et al.

Outcomes of patients with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

106

.

67.

Iacoboni

G

,

Rejeski

K

,

Villacampa

G

, et al.

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

.

Blood Adv

.

2022

;

6

(

12

):

3606

-

3610

.

68.

Wang

Y

,

Jain

P

,

Locke

FL

, et al.

Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US Lymphoma CAR T Consortium [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

744

.

69.

Wang

M

,

Munoz

J

,

Goy

A

, et al.

KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma

.

N Engl J Med

.

2020

;

382

(

14

):

1331

-

1342

.

70.

Wang

Y

,

Jain

P

,

Locke

FL

, et al.

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium

.

J Clin Oncol

.

2023

;

41

(

14

):

2594

-

2606

.

71.

Wang

M

,

Siddiqi

T

,

Gordon

LI

, et al.

Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study

.

J Clin Oncol

.

2023

;

42

(

10

):

1146

-

1157

.

72.

Minson

AG

,

Hamad

N

,

Cheah

CY

, et al.

T-cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: phase II TARMAC study

.

Blood

.

2024

;

143

(

8

):

673

-

684

.

73.

Wang

M

,

Jurczak

W

,

Trneny

M

, et al.

Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study

.

J Clin Oncol

.

2024

;

42

(

suppl 16

):

7007

.

74.

Lin

RJ

,

Ho

C

,

Hilden

PD

, et al.

Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations

.

Br J Haematol

.

2019

;

184

(

6

):

1006

-

1010

.

75.

Robinson

SP

,

Boumendil

A

,

Finel

H

, et al.

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party

.

Bone Marrow Transplant

.

2018

;

53

(

5

):

617

-

624

.

76.

Moreau

P

,

Garfall

AL

,

van de Donk

N

, et al.

Teclistamab in relapsed or refractory multiple myeloma

.

N Engl J Med

.

2022

;

387

(

6

):

495

-

505

.

77.

Kantarjian

H

,

Stein

A

,

Gökbuget

N

, et al.

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia

.

N Engl J Med

.

2017

;

376

(

9

):

836

-

847

.

78.

Hutchings

M

,

Morschhauser

F

,

Iacoboni

G

, et al.

Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial

.

J Clin Oncol

.

2021

;

39

(

18

):

1959

-

1970

.

79.

Budde

LE

,

Sehn

LH

,

Matasar

M

, et al.

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

.

Lancet Oncol

.

2022

;

23

(

8

):

1055

-

1065

.

80.

Phillips

TJ

,

Dickinson

M

,

Morschhauser

F

, et al.

Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

178

-

180

.

81.

Godwin

CD

,

Bates

OM

,

Garling

EE

,

Beddoe

ME

,

Laszlo

GS

,

Walter

RB

.

The Bruton’s tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity

.

Br J Haematol

.

2020

;

189

(

1

):

e9-e13

.

82.

Phillips

TJ

,

Matasar

M

,

Eyre

TA

, et al.

GLOBRYTE: a phase III, open-label, multicenter, randomized trial evaluating glofitamab monotherapy in patients with relapsed or refractory mantle cell lymphoma [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

3052

.

83.

Clausen

MR

,

Lugtenburg

P

,

Hutchings

M

, et al.

Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity

.

J Clin Oncol

.

2021

;

39

(

suppl 15

):

7518

.

84.

Bannerji

R

,

Arnason

JE

,

Advani

RH

, et al.

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

.

Lancet Haematol

.

2022

;

9

(

5

):

e327

-

e339

.

85.

Budde

LE

,

Assouline

S

,

Sehn

LH

, et al.

Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study

.

J Clin Oncol

.

2022

;

40

(

5

):

481

-

491

.

86.

Hamadani

M

,

Radford

J

,

Carlo-Stella

C

, et al.

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

.

Blood

.

2021

;

137

(

19

):

2634

-

2645

.

87.

Spurgeon

S

,

Mei

M

,

Barr

PM

, et al.

P1200: zilovertamab vedotin (MK-2140) in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): updated results from the phase 1 waveline-001 study

.

HemaSphere

.

2023

;

7

(

S3

):

e54506b2

.

88.

Zinzani

PL

,

Mayer

J

,

Benjamini

O

, et al.

A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies: waveLINE-006

.

Hematol Oncol

.

2023

;

41

(

S2

):

564

-

565

.

89.

Hess

G

,

Dreyling

M

,

Oberic

L

, et al.

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

.

Leuk Lymphoma

.

2024

;

65

(

1

):

14

-

25

.